In January this year, many will remember Emmanuel Macron telling reporters, in no uncertain terms, what he thought about the vaccine developed by AstraZeneca and Oxford University.
“Today we think that it is quasi-ineffective for people over 65”, he said, hours before the European Medicines Agency recommended it for adults of all ages. “[T]he early results we have are not encouraging for 60 to 65-year-old people concerning AstraZeneca”, the French president warned, as well as criticising Britain’s strategy of delaying the second dose of the vaccine to get the first one out quickly – in another act of incredible diplomacy.
Days earlier a German newspaper incorrectly claimed the AstraZeneca jab is only eight per cent effective in the over-65s. While the figure was quickly dismissed, several countries haven’t exactly inspired confidence in AstraZeneca’s efficacy. Germany advised that it should not be given to people aged 65 or above, citing “insufficient data”, and France, Switzerland, Denmark, Sweden and Norway have also recommended it only for younger people.
Ursula von der Leyen, the European Commission Chief, even went so far as to accuse the UK of compromising on “safety and efficacy” safeguards in delivering its vaccines. And Clément Beaune, France’s Europe Minister, warned “the British are in an extremely difficult health situation. They are taking many risks in this vaccination campaign.” You don’t have to be a Brexiteer to get the idea: British vaccines = bad. Even John Bell, a medical professor at Oxford University, accused Macron trying to reduce demand for vaccines to cover up the EU’s huge issues with procurement, culminating in its dangerous attempt to control vaccine exports across the Irish border.
So one wonders what the mood is in Brussels now that research has revealed just what a success the much-attacked AstraZeneca vaccine has been. A study in Scotland, where 1.14 million people were vaccinated between December 8 and February 15, showed that both the AstraZeneca and Pfizer vaccines led to a “very substantial” drop in serious illness across all adult age groups.
Critically, researchers found that by the fourth week after receiving an initial dose of each vaccine, the risk of hospitalisation from Covid-19 reduced by up to 85 per cent (Pfizer) and 94 per cent (AstraZeneca), in a result that will please people who’ve had it – but raise serious questions about the language and policies of EU leaders.
In January, the EU very publicly complained when AstraZeneca said there would be a delay to its vaccine supply. Now, in some EU member states, not all AZ jabs they have are being used. We wanted to return to the story. Produced @michaelcoxj https://t.co/ydJg8xyDxt pic.twitter.com/qH00n20ZaT
— Ros Atkins (@BBCRosAtkins) February 23, 2021
Their actions have fuelled vaccine hesitancy. In Germany, for instance, people have failed to turn up to appointments for the AstraZeneca vaccine. As of Friday, only 150,000 out of 1.5 million doses of the vaccine had been used – leaving the country with less than six per cent of its population immunised (compared to 26 per cent for Britain).
There are also reports of hospital workers in France and Belgium demanding that they be given the Pfizer jab instead of AstraZeneca (one nurse in a Flemish hospital even told a publication she would go on strike if offered the latter). Politicians have failed to convey the bigger picture; that everyone is lucky to be offered one vaccine with high efficacy rates (50 per cent protection would have been a good outcome), let alone that several have been developed.
As Ryan Bourne and Jethro Elsden have already written for ConservativeHome, the EU’s difficulties in procuring vaccines is dangerous enough in itself – Bourne estimates the UK has saved around nine thousand lives by choosing its own vaccination programme, and Elsden says the country has gained approximately £100 billion from doing this.
The fact that some EU leaders have added to this chaos by planting doubts about AstraZeneca’s vaccine makes the situation even more alarming. The vulnerable are less protected, and – on a global scale – if we do not get transmission of the virus down, it can mutate and mean that the current vaccines do not work.
Some leaders realise the seriousness of the problem. Michael Müller, the mayor of Berlin, has warned that people could be sent to the back of the queue for vaccines if they refuse an AstraZeneca job. “I won’t allow tens of thousands of doses to lie around on our shelves while millions of people across the country are waiting to be immunised”, were his words, and Angela Merkel’s spokesman has pleaded with Germans to take the “safe and highly effective” jab.
It’s a start, but terrible that so much damage has already been done. Some might remember that in November 2020, MPs here debated whether social media companies should be doing more to remove anti-vaccine disinformation. Never could they have imagined it would be Macron spreading some of the most troublesome ideas.